NCT03553342

Brief Summary

Thyroidectomy is a common surgical procedure in France. Recurrent paralysis is one of the main complications. Oral corticosteroid therapy are frequently used at a dosage of 1mg/kg for seven days, in case of recurrent paralysis to obtain remobilization as early as possible. The main objective is to evaluate the efficacy of oral corticosteroid therapy in remobilization of vocal cords at seven days in patients with unilateral recurrent paralysis after thyroidectomy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
156

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Sep 2018

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 23, 2018

Completed
20 days until next milestone

First Posted

Study publicly available on registry

June 12, 2018

Completed
3 months until next milestone

Study Start

First participant enrolled

September 11, 2018

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 11, 2021

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 11, 2022

Completed
Last Updated

January 29, 2021

Status Verified

January 1, 2021

Enrollment Period

3 years

First QC Date

May 23, 2018

Last Update Submit

January 28, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Evaluate the efficacy of oral corticosteroid in remobilization of vocal cords at seven days for patients with unilateral recurrent laryngeal nerve palsy after thyroidectomy

    evaluated by naso fibroscope inspection

    Seven days

Study Arms (2)

Corticoids

EXPERIMENTAL
Drug: Corticoids

Placebo

PLACEBO COMPARATOR
Other: Placebo

Interventions

Patients will receive corticosteroids therapy: 1mg/kg of prednisolone daily for seven days.

Corticoids
PlaceboOTHER

Patients will receive placebo for seven days.

Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients scheduled for simple total thyroidectomy or lobo-isthmectomy
  • Patients over eighteen years old
  • Free subject, whitout tutorship or curatorship or subordination
  • Informed consent and signed by the patient after clear and fair information about the study.

You may not qualify if:

  • Patients operated on a total thyroidectomy with médiastino-recurrent dissection for cancer etiology
  • Patients with preoperative recurrent paralysis
  • Patients with hypersensitivity to prednisolone or any of the excipients.
  • Patients with contraindication to use Solupred
  • Patients with anti-inflammatory of acetylsalicylic acid
  • Patient with evolving virosis (hepatitis, herpes, chicken pox, zoster)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chu Poitiers

Poitiers, France

RECRUITING

Related Publications (1)

  • Carvajal-Alegria E, Girault N, Donatini G, Frasca D, Tonnerre D, Cosset T, Rulliere A, Lebreton JP, Dufour X, Carsuzaa F. Oral Corticosteroids in Vocal Fold Paralysis After Thyroid Surgery: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2025 Sep 1;151(9):874-880. doi: 10.1001/jamaoto.2025.2169.

MeSH Terms

Conditions

Vocal Cord Paralysis

Interventions

Adrenal Cortex Hormones

Condition Hierarchy (Ancestors)

Laryngeal DiseasesRespiratory Tract DiseasesOtorhinolaryngologic DiseasesVagus Nerve DiseasesCranial Nerve DiseasesNervous System DiseasesParalysisNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

HormonesHormones, Hormone Substitutes, and Hormone Antagonists

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 23, 2018

First Posted

June 12, 2018

Study Start

September 11, 2018

Primary Completion

September 11, 2021

Study Completion

January 11, 2022

Last Updated

January 29, 2021

Record last verified: 2021-01

Locations